Home > Publications database > Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group. > print

001     288867
005     20251023134511.0
024 7 _ |a 10.1093/neuonc/noae049
|2 doi
024 7 _ |a pmid:38466087
|2 pmid
024 7 _ |a 1522-8517
|2 ISSN
024 7 _ |a 1523-5866
|2 ISSN
024 7 _ |a altmetric:160675588
|2 altmetric
037 _ _ |a DKFZ-2024-00514
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Galldiks, Norbert
|0 0000-0002-2485-1796
|b 0
245 _ _ |a Challenges, Limitations and Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A Report of the PET/RANO Group.
260 _ _ |a Oxford
|c 2024
|b Oxford Univ. Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1720430728_6946
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2024 Jul 5;26(7):1181-1194
520 _ _ |a Brain tumor diagnostics have significantly evolved with the use of PET and advanced MRI techniques. In addition to anatomical MRI, these modalities may provide valuable information for several clinical applications such as differential diagnosis, delineation of tumor extent, prognostication, differentiation between tumor relapse and treatment-related changes, and the evaluation of response to anticancer therapy. In particular, joint recommendations of the RANO group, the EANO, and major European and American Nuclear Medicine societies highlighted that the additional clinical value of radiolabeled amino acids compared to anatomical MRI alone is outstanding and that its widespread clinical use should be supported. For advanced MRI and its steadily increasing use in clinical practice, the Standardization Subcommittee of the Jumpstarting Brain Tumor Drug Development Coalition provided more recently an updated acquisition protocol for the widely used dynamic susceptibility contrast perfusion MRI. Besides amino acid PET and perfusion MRI, other PET tracers and advanced MRI techniques (e.g., MR spectroscopy) are of considerable clinical interest and are increasingly integrated into everyday clinical practice. Nevertheless, these modalities have shortcomings which should be considered in clinical routine. This comprehensive review provides an overview of potential challenges, limitations and pitfalls associated with PET imaging and advanced MRI techniques in patients with gliomas or brain metastases. Despite these issues, PET imaging and advanced MRI techniques continue to play an indispensable role in brain tumor management. Acknowledging and mitigating these challenges through interdisciplinary collaboration, standardized protocols, and continuous innovation will further enhance the utility of these modalities in guiding optimal patient care.
536 _ _ |a 899 - ohne Topic (POF4-899)
|0 G:(DE-HGF)POF4-899
|c POF4-899
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a CEST
|2 Other
650 _ 7 |a MR spectroscopy
|2 Other
650 _ 7 |a amino acid PET
|2 Other
650 _ 7 |a diffusion-weighted imaging
|2 Other
650 _ 7 |a perfusion-weighted imaging
|2 Other
700 1 _ |a Kaufmann, Timothy J
|b 1
700 1 _ |a Vollmuth, Philipp
|b 2
700 1 _ |a Lohmann, Philipp
|0 0000-0002-5360-046X
|b 3
700 1 _ |a Smits, Marion
|0 0000-0001-5563-2871
|b 4
700 1 _ |a Veronesi, Michael C
|b 5
700 1 _ |a Langen, Karl-Josef
|b 6
700 1 _ |a Rudá, Roberta
|b 7
700 1 _ |a Albert, Nathalie L
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Hattingen, Elke
|b 9
700 1 _ |a Law, Ian
|b 10
700 1 _ |a Hutterer, Markus
|b 11
700 1 _ |a Soffietti, Riccardo
|0 0000-0002-9204-7038
|b 12
700 1 _ |a Vogelbaum, Michael A
|b 13
700 1 _ |a Wen, Patrick Y
|b 14
700 1 _ |a Weller, Michael
|0 0000-0002-1748-174X
|b 15
700 1 _ |a Tonn, Joerg-Christian
|0 P:(DE-HGF)0
|b 16
773 _ _ |a 10.1093/neuonc/noae049
|g p. noae049
|0 PERI:(DE-600)2094060-9
|n 7
|p 1181-1194
|t Neuro-Oncology
|v 26
|y 2024
|x 1522-8517
856 4 _ |u https://inrepo02.dkfz.de/record/288867/files/noae049.pdf
856 4 _ |u https://inrepo02.dkfz.de/record/288867/files/noae049.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:inrepo02.dkfz.de:288867
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2024
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-24
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURO-ONCOLOGY : 2022
|d 2023-10-24
920 1 _ |0 I:(DE-He78)MU01-20160331
|k MU01
|l DKTK Koordinierungsstelle München
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)MU01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21